{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:39:44Z","timestamp":1784151584859,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113457","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:31:53Z","timestamp":1700494313000},"page":"113457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2822-4466","authenticated-orcid":false,"given":"Diego","family":"de Miguel-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-9957","authenticated-orcid":false,"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0648-3983","authenticated-orcid":false,"given":"William","family":"Grier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-0620","authenticated-orcid":false,"given":"Pasquale","family":"Pisapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-9470","authenticated-orcid":false,"given":"Gianluca","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Culligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Scilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranee","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranshu","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1164-3779","authenticated-orcid":false,"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-8740","authenticated-orcid":false,"given":"Ashutosh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7860-8417","authenticated-orcid":false,"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejca.2023.113457_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113457_bib2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.113457_bib3","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1136\/jitc-2021-003956","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma","volume":"10","author":"Govindan","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2023.113457_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2023.113457_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jtho.2019.04.029","article-title":"A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint national cancer institute-international association for the study of lung cancer-mesothelioma applied research foundation taskforce","volume":"14","author":"Friedberg","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.113457_bib6","unstructured":"M. Carbone, H.I. Pass, G. Ak\u00a0et al., Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations J Thorac Oncol 17 7 2022 873 889 doi:\u00a010.1016\/J.JTHO.2022.03.014\/ATTACHMENT\/0815A55B-244E\u20134BEE-9AE3-5CD73751FD54\/MMC3.DOCX."},{"issue":"12","key":"10.1016\/j.ejca.2023.113457_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ejca.2023.113457_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ejca.2023.113457_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010229","article-title":"Contemporary trends in malignant peritoneal mesothelioma: incidence and survival in the United States","volume":"15","author":"Calthorpe","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ejca.2023.113457_bib10","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2018.08.007","article-title":"Survival by histologic subtype of malignant pleural mesothelioma and the impact of surgical resection on overall survival","volume":"19","author":"Verma","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"10272","key":"10.1016\/j.ejca.2023.113457_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejca.2023.113457_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113457_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2023.113457_bib14","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2023.113457_bib15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"issue":"30","key":"10.1016\/j.ejca.2023.113457_bib16","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2018.78.1963","article-title":"Tumor mutation burden as a biomarker in resected non-small-cell lung cancer","volume":"36","author":"Devarakonda","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113457_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bjc.2017.8","article-title":"Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients","volume":"116","author":"Malapelle","year":"2017","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2023.113457_bib18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/cncy.22400","article-title":"Tumor mutational burden on cytological samples: a pilot study","volume":"129","author":"Pepe","year":"2021","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113457_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06841-0","article-title":"Survival Genie, a web platform for survival analysis across pediatric and adult cancers","volume":"12","author":"Dwivedi","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2023.113457_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med"},{"issue":"11","key":"10.1016\/j.ejca.2023.113457_bib21","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2023.113457_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34339","article-title":"Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: the EPIC prospective cohort","volume":"152","author":"Allione","year":"2023","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2023.113457_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.113457_bib24","doi-asserted-by":"crossref","first-page":"v475","DOI":"10.1093\/annonc\/mdz253","article-title":"Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies","volume":"30","author":"Diaz","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113457_bib25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","article-title":"Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study","volume":"9","author":"Calabr\u00f2","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ejca.2023.113457_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.113457_bib27","article-title":"Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes","volume":"25","author":"Markowitz","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"9","key":"10.1016\/j.ejca.2023.113457_bib28","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1136\/jitc-2021-003032","article-title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2023.113457_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ejca.2023.113457_bib30","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/cancers14112816","article-title":"Mutations in KMT2C, BCOR and KDM5C predict response to immune checkpoint blockade therapy in non\u2010small cell lung cancer","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.113457_bib31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2147\/OTT.S381825","article-title":"Molecular characteristics and the effect of KRAS mutation on the prognosis of immunotherapy in non-small cell lung cancer in Xinjiang, China","volume":"15","author":"Gu","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"47","key":"10.1016\/j.ejca.2023.113457_bib32","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.ejca.2023.113457_bib33","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.ejca.2023.113457_bib34","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(18)30648-X","article-title":"Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study","volume":"19","author":"Voss","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113457_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/KCA-160003","article-title":"Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell carcinoma","volume":"1","author":"Carlo","year":"2017","journal-title":"Kidney Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.113457_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-011-0950-8","article-title":"Germline PKHD1 mutations are protective against colorectal cancer","volume":"129","author":"Ward","year":"2011","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.ejca.2023.113457_bib37","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.gendis.2021.04.003","article-title":"Targeting LIF\/LIFR signaling in cancer","volume":"9","author":"Viswanadhapalli","year":"2022","journal-title":"Genes Dis"},{"issue":"10","key":"10.1016\/j.ejca.2023.113457_bib38","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3390\/cancers13102445","article-title":"Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: a feasibility study","volume":"13","author":"Moretti","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ejca.2023.113457_bib39","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.ejca.2023.113457_bib40","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1111\/jcmm.17445","article-title":"Pbrm1 intrinsically controls the development and effector differentiation of iNKT cells","volume":"26","author":"Wang","year":"2022","journal-title":"J Cell Mol Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:01Z","timestamp":1760733781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"alternative-id":["S0959804923007591"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113457","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113457"}}